Gilead Sciences, Inc. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Gilead Sciences vs. Supernus Pharmaceuticals

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, Gilead Sciences, Inc. and Supernus Pharmaceuticals, Inc. have shown distinct approaches to handling these costs. Gilead Sciences, with its expansive operations, reported a steady increase in SG&A expenses, peaking at approximately $6.09 billion in 2023. This represents a 104% increase from 2014, reflecting its strategic investments in marketing and administration.

Conversely, Supernus Pharmaceuticals, a smaller player, demonstrated a more conservative growth in SG&A expenses, reaching around $336 million in 2023. This is a significant 364% rise from 2014, indicating aggressive scaling efforts. While Gilead's larger scale allows for higher absolute spending, Supernus's rapid percentage increase highlights its dynamic growth strategy. Understanding these trends offers valuable insights into each company's operational priorities and market positioning.